Zhuang Z, Chen Y, Liu Z, Fu Y, Wang F, Bai L
Heliyon. 2025; 10(14):e34392.
PMID: 39816356
PMC: 11734065.
DOI: 10.1016/j.heliyon.2024.e34392.
Armstrong A, Tang Y, Mukherjee N, Zhang N, Huang G
Front Immunol. 2024; 15:1448201.
PMID: 39318634
PMC: 11420043.
DOI: 10.3389/fimmu.2024.1448201.
Nelson A, Wang L, Laffey K, Becher L, Parks C, Hoffmann M
Front Immunol. 2024; 15:1434463.
PMID: 39281668
PMC: 11392757.
DOI: 10.3389/fimmu.2024.1434463.
Casagrande S, Sopetto G, Bertalot G, Bortolotti R, Racanelli V, Caffo O
Cancers (Basel). 2024; 16(7).
PMID: 38611115
PMC: 11011060.
DOI: 10.3390/cancers16071440.
Zhang Y, Wen X, Ouyang Y, Hu Y, Fang X, Zhang J
Heliyon. 2024; 10(2):e24380.
PMID: 38293388
PMC: 10826737.
DOI: 10.1016/j.heliyon.2024.e24380.
Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment.
Guo X, Wu Y, Xue Y, Xie N, Shen G
Front Immunol. 2023; 14:1291836.
PMID: 38106416
PMC: 10722299.
DOI: 10.3389/fimmu.2023.1291836.
Nanoparticles and cytokine response.
Nasrullah M, Sundaram D, Claerhout J, Ha K, Demirkaya E, Uludag H
Front Bioeng Biotechnol. 2023; 11:1243651.
PMID: 37701495
PMC: 10493271.
DOI: 10.3389/fbioe.2023.1243651.
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
Tapia-Galisteo A, Alvarez-Vallina L, Sanz L
J Hematol Oncol. 2023; 16(1):83.
PMID: 37501154
PMC: 10373336.
DOI: 10.1186/s13045-023-01482-w.
Nanotargeted Delivery of Immune Therapeutics in Type 1 Diabetes.
Jung S, Ben Nasr M, Bahmani B, Usuelli V, Zhao J, Sabiu G
Adv Mater. 2023; 35(40):e2300812.
PMID: 37357903
PMC: 10629472.
DOI: 10.1002/adma.202300812.
TriTECM: A tetrafunctional T-cell engaging antibody with built-in risk mitigation of cytokine release syndrome.
Carrara S, Harwardt J, Grzeschik J, Hock B, Kolmar H
Front Immunol. 2022; 13:1051875.
PMID: 36439165
PMC: 9687101.
DOI: 10.3389/fimmu.2022.1051875.
Acute kidney injury and electrolyte disorders in COVID-19.
Nogueira G, Silva N, Moura A, Duarte Silveira M, Moura-Neto J
World J Virol. 2022; 11(5):283-292.
PMID: 36188735
PMC: 9523327.
DOI: 10.5501/wjv.v11.i5.283.
Stage 4 Cytokine Release Syndrome Caused by the First Dose of Nivolumab and Ipilimumab Combination Therapy in a Patient with Metastatic Melanoma Successfully Treated with Methylprednisolone, Tocilizumab, and Etanercept.
Menakuru S, Azeem Q, Priscu A, Khan I, Beirat A
Case Rep Oncol. 2022; 15(2):648-653.
PMID: 35949898
PMC: 9294929.
DOI: 10.1159/000525173.
100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes.
Pearson J, McKinney E, Walker L
Immunother Adv. 2022; 1(1):ltab024.
PMID: 35156097
PMC: 8826223.
DOI: 10.1093/immadv/ltab024.
Screening of Microbial Natural Products and Biological Evaluation of Trichomicin as Potential Anti-Cytokine Storm Agents.
Chen Y, Zhuang Z, Yang J, Bai L
Front Pharmacol. 2021; 12:770910.
PMID: 34955842
PMC: 8696163.
DOI: 10.3389/fphar.2021.770910.
Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences.
Anderson Tvedt T, Vo A, Bruserud O, Reikvam H
J Clin Med. 2021; 10(21).
PMID: 34768710
PMC: 8585070.
DOI: 10.3390/jcm10215190.
The Many Faces of Cytokine Release Syndrome-Related Coagulopathy.
Wang J, Doran J
Clin Hematol Int. 2021; 3(1):3-12.
PMID: 34595461
PMC: 8432322.
DOI: 10.2991/chi.k.210117.001.
The state of the art of bispecific antibodies for treating human malignancies.
Wang S, Chen K, Lei Q, Ma P, Yuan A, Zhao Y
EMBO Mol Med. 2021; 13(9):e14291.
PMID: 34431224
PMC: 8422067.
DOI: 10.15252/emmm.202114291.
Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy.
Blanco B, Dominguez-Alonso C, Alvarez-Vallina L
Clin Cancer Res. 2021; 27(20):5457-5464.
PMID: 34108185
PMC: 9306338.
DOI: 10.1158/1078-0432.CCR-20-3770.
Differential association between inflammatory cytokines and multiorgan dysfunction in COVID-19 patients with obesity.
Dragon-Durey M, Chen X, Kirilovsky A, Ben Hamouda N, El Sissy C, Russick J
PLoS One. 2021; 16(5):e0252026.
PMID: 34038475
PMC: 8153504.
DOI: 10.1371/journal.pone.0252026.
5-Hydroxytryptamine, Glutamate, and ATP: Much More Than Neurotransmitters.
Franco R, Rivas-Santisteban R, Lillo J, Camps J, Navarro G, Reyes-Resina I
Front Cell Dev Biol. 2021; 9:667815.
PMID: 33937270
PMC: 8083958.
DOI: 10.3389/fcell.2021.667815.
